**Invited Review**

Mediators of Inflammation, 1, 295–308 (1992)

Cytokines and eicosanoid products of macrophages play an essential role in expression of antitumour activity of macrophages either in a cell-to-cell contact system between the effector and the target cell or as cell-free soluble products. In this review the relationship between three main monokines, namely TNF-α, IL-1 and IL-6 and the interrelationship between these monokines and eicosanoids (PGE₂, PGI₂, LTB₄, LTC₄) in their production and in expression of antitumour activity is discussed. Emphasis is given to the effect of tumour burden on production of the monokines and of the eicosanoids and on the production of these compounds by the tumour cells. Finally, the therapeutic implications drawn from animal studies and clinical trials is discussed.

**Keywords:** Antitumour activity, Cancer immunotherapy, Cytokines, Eicosanoids, IL-1, IL-6, Leukotrienes, LTB₄, LTC₄, Macrophages, Monokines, PGE₂, Prostaglandins, TNF-α

---

**Interactions between macrophage cytokines and eicosanoids in expression of antitumour activity**

Shlomo Ben-Efraim

Department of Pharmacology, Faculty of Medicine, Erasmus University, 3000 DR Rotterdam, The Netherlands

Permanent Address: Department of Human Microbiology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel

---

**Introduction**

Since the pioneering work of Metchnikoff, it became more and more evident that macrophage cells play an essential role in a wide array of biological activities. This includes among others the events of nonspecific resistance against invasion of foreign cells (including tumour cells), their function as a crucial mediator in the development of immune response and participation in the process of inflammation (for review see Ref. 2).

The various functions of macrophages are exerted either in a cell-to-cell contact set-up with the target cells or by various biologically and pharmacologically active factors released by these cells. Among the most salient factors released by macrophages are various monokines and products of arachidonic acid (prostaglandins and leukotrienes).

An extensive amount of work has been done on the pharmacological and biological effects of macrophage cytokines and eicosanoids. The present review is by no means intended to provide a full coverage of all the activities of macrophage cytokines and eicosanoids. The aim is to discuss only the topic of interrelation between certain macrophage cytokines and eicosanoids in the context of their expression of antitumour activity. The main emphasis will be on the role of macrophage cytokines tumour necrosis factor-α (TNF-α) interleukin-1 (IL-1) and interleukin-6 (IL-6) and on the role of prostaglandin E₂ (PGE₂), leukotriene B₄ (LTB₄) and leukotriene C₄ (LTC₄) and their interrelation in the production and expression of antitumour activity. Another aspect to be discussed is the effect of tumour burden on their production by macrophages, production of these compounds by tumour cells and their therapeutic effectiveness in experimental tumour models and in cancer patients.

The first indications on induced release of certain antitumour factors by bacteria-free filtrates came for the early work of Coley (for review see Ref. 3). Later on, Carswell et al.⁴ reported the occurrence of an antitumour cytotoxic factor in the serum of mice which had undergone treatment with bacterial lipopolysaccharide (LPS), coined the term tumour necrosis factor (TNF) and suggested that TNF is produced by activated macrophages in response to LPS. The occurrence of a lymphocyte activated factor produced by macrophages was first reported in 1972⁵,⁶ and was named lymphocyte activating factor (LAF). In 1979, the nomenclature of various cytokines was revised⁷ and the former LAF was given the name of IL-1 which is still used today. IL-6 was initially described as a factor derived from fibroblasts with antiviral activity.⁸ The term IL-6 was first suggested by Poupart and colleagues⁹ and its production by human monocytes was reported.¹⁰

---

**Interactions in the production of macrophage cytokines and eicosanoids**

Interactions in production between TNF-α, IL-1 and IL-6: It has been reported that production from blood mononuclear cells and from peritoneal macrophages of TNF-α, IL-1 and IL-6, can be induced by the same stimulatory agents. This applies to LPS,¹¹-¹³ phytohaemagglutinin (PHA)¹⁴
and *Staphylococcus epidermis*. It should be noted also that the same monokine can be induced by different mechanisms. Thus, it was reported that *Mycoplasma capricolum* membranes induced TNF-α by a mechanism different from induction by LPS.

In spite of the similarities in stimulation of the production of the monokines, some differences were reported in the context of their production. These differences indicate that mechanisms of their production may be different. Thus, human monocytes stimulated with pneumococcal cell surface components produced IL-1 but not TNF-α. Both protein kinase C (PKc) and calmodulin (CaM) kinase dependent pathways were found to be involved in the induction of IL-1 mRNA by LPS, whereas TNF-α expression seemed to be PKc dependent but not CaM kinase dependent. Other authors reported that TNF-α and IL-1 production and secretion by mononuclear phagocytes can be modulated differentially. Differences between the kinetics of production of IL-1α, IL-1β and TNF-α by murine peritoneal macrophages during the peritoneal exudative response, were also described in relation to the optimal culture conditions and sequence of appearance. The production of TNF-α and IL-1 in alveolar human macrophages was found to be regulated differentially by LPS. A different pattern of regulation was also observed in the case of human macrophages: during the initial phase of maturation of human blood monocytes (up to 7 days in culture), IL-1β and IL-6 were down-regulated whereas TNF-α levels markedly increased. A synergistic effect of interferon-γ (IFN-γ) and LPS was observed in relation to the release of IL-1β, IL-6 and TNF-α from human macrophages. However, the LPS-induced levels of these cytokines differed during prolonged cultivation of macrophages (up to 28 days). Differences in levels of production of IL-1α, IL-1β and TNF-α versus lower levels of IL-6 were also reported following stimulation by various agents of human blood mononuclear cells.

The relationship in production between TNF-α, IL-1β and IL-6 is expressed by the findings that each one of these monokines can affect the production of the other monokines. Thus TNF-α was found to induce release of IL-1 in *vivo* and *in vitro*. TNF-α and IL-1 induced IL-6 production in *vivo*. Stimulation of human monocytes by IL-1 caused a rapid down-regulation of IL-6 mRNA levels and concomitant enhancement of IL-6 mRNA expression. IL-6 itself was found to suppress the IL-6-R at high concentrations. IL-6 suppressed IL-1β and TNF-α production induced by LPS or PHA in human blood mononuclear cells. Inhibition of LPS-induced TNF production by IL-6 in cultured human monocytes was also reported by other authors. By working with bone marrow derived mouse macrophages it was found that LPS induces secretion of both TNF-α, IL-1 and IL-6. IL-1 was able to stimulate IL-6 synthesis in human blood monocytes but not in monocyte derived macrophages whereas TNF-α had no effect on IL-6 synthesis in monocytes or macrophages. Human alveolar macrophages and blood monocytes produced large amounts of IL-6 in response to LPS and monocytes produced lesser amounts of IL-6 in response to rIL-1. Monocytes aged in *vitro* produced little detectable IL-6 in response to LPS or rIL-1, which might suggest that release of IL-6 under stimulus is correlated to the degree of maturity of macrophage cells. TNF-α or rIL-6 itself did not modulate IL-6 production in human peripheral blood mononuclear cells. No evidence was found that TNF-α acts to amplify the production of IL-6 or IL-1 by murine macrophage cell lines. It was also claimed that synthesis and secretion of IL-1 either by human monocytes or by mouse bone marrow derived macrophages are two different biological events.

Similarly, LPS-induced production of TNF-α and IL-1 was also reported in human peritoneal macrophages collected from patients on continuous ambulatory peritoneal dialysis (CAPD) during an episode of infectious peritonitis.

The conclusion from the above-mentioned data is that TNF-α, IL-1 and IL-6 can mutually affect their production. The production and release of these cytokines are also affected by other agents (including other cytokines) but these findings are beyond the scope of the present review. A schematic representation of the interrelationship in production between the three cytokines is given in Fig. 1.

![Schematic Representation of Intercellular Cytokine Network](image)
Monokines, eicosanoids and antitumour activity

Interactions in production between cytokines and eicosanoids: A series of findings indicated that production of TNF-α by macrophages can be regulated by both endogenous and exogenous PGE2. Thus, in response to LPS, murine peritoneal macrophages release concomitantly increased amounts of TNF-α and PGE2. However, addition of exogenous PGE2 strongly suppressed the release of TNF-α by macrophages. PGE2 down-regulated the expression of TNF-α gene in human blood monocytes.

In another work it was reported that low amounts of PGE2 enhanced release of TNF-α from macrophages whereas high doses of PGE2 suppress its release. Some authors reported recently that the gene expression of TNF-α was enhanced by low doses of PGE2 and by cGMP, and suggested that cGMP may represent one of the positive signals for TNF-α synthesis.

Suppression of LPS-induced TNF-α production by PGE2 was also reported by other authors. The inhibitory effect of PGE2 on TNF-α production was correlated with induced augmentation of cAMP in macrophage cells. In contrast to PGE2, leukotrienes induce increases in TNF-α release from macrophages. Thus, human monocytes exposed to graded concentrations of LTB4 release high amounts of TNF-α. The enhancing effect of leukotrienes on TNF-α may be related to increases in cGMP levels by leukotrienes and is also supported by findings that lipoxynagenase inhibitors suppress formation of TNF-α in vitro and in vivo.

Treatment of macrophages with LPS enhanced the increase of a lipoxynagenase product which counteracted the suppression of TNF-α synthesis by a lipoxynagenase inhibitor when added to macrophages exogenously. Recent data suggest that endogenous prostaglandins and leukotrienes do not play a role in the regulation of TNF-α production. In addition indomethacin (IND) (a cyclooxygenase inhibitor), exogenous arachidonate and MK-886 (a novel inhibitor of 5-lipoxygenase product formation) do not affect TNF-α production. The interrelationship between TNF-α and PGE2 production is also supported by the finding that TNF-α stimulates PGE2 production in murine resident peritoneal macrophages. Other data indicate that enhancement of TNF-α activity may be independent of PGE2 production. Thus IFN-γ in combination with LPS enhanced TNF-α production but addition of IFN-γ to LPS had no effect on PGE2 levels produced in human monocytes.

With regard to IL-1, it was found that the same stimulator, namely PHA, induced production of both IL-1 and prostaglandin E in human monocyte monolayers. Products of the cyclooxygenase pathway of arachidonate metabolism seem not to be involved in the mechanism by which IL-1 stimulates thymocyte proliferation, whereas products of the lipoxynagenase pathway may mediate the thymocyte proliferative response induced by IL-1.

Similarly, with TNF-α, it seems that an arachidonate lipoxynagenase product is important in the sequence of events leading to the production of IL-1. Additionally lipoxynagenase inhibitors affected production of IL-1 in human peripheral blood monocytes. An enhancing role of leukotrienes in production of IL-1 was also advocated by other authors.

Recently, it was reported that addition of exogenous LTB4 to monocytes stimulates IL-1β transcription and mRNA accumulation. A self-regulatory mechanism of IL-1 production was suggested by data showing that exogenous IL-1 induces increases in the levels of PGE2 in murine macrophage cultures, whereas exogenous PGE2 or prostacyclin (PGI2) (measured as its stable metabolite 6-keto prostaglandin F1α) suppressed macrophage IL-1 production. The inhibitory effect of PGE2 was correlated to induce increases in cAMP levels. IL-1 was found, on the other hand, to stimulate 5-lipoxygenase activity and in this way induces increases in PGE2 synthesis. In contrast to these data, it was also reported that PGE2 had no effect on IL-1 synthesis in murine resident peritoneal macrophages but rather had a direct inhibitory effect on thymocyte proliferation.

In spite of the similarities in the stimulating conditions for production of TNF-α and IL-1 some differences were also reported. Thus, it was claimed that PGE2 suppresses expression of cell-associated TNF-α in murine peritoneal macrophages but had no effect on cell-associated IL-1 activity.

The production of IL-6 concomitantly to production of PGE2 in LPS-stimulated rat Kupffer cells was examined. IL-6 production increased in...
FIG. 2. Schematic representation of interrelationship in production by macrophages between cytokines (TNFα, IL-1 and IL-6) and eicosanoids (PGE₂; LT: leukotrienes); +: enhancement; -: inhibition; *+: at low doses, at high doses.

parallel with PGE₂ before decreasing as PGE₂ continued to rise. Blocking of PGE₂ production by IND increased IL-6 levels significantly thus showing that PGE₂ produced by Kupffer cells down-regulates IL-6 secretion. However, cyclooxygenase inhibitors inhibited production of IL-6 by human peripheral blood mononuclear cells, but no direct relationship between inhibition of IL-6 and production of PGE₂ was found. Leukotrienes stimulate production of IL-6 in cultures of human monocytes. LTB₄ stimulates production of IL-6 and induces accumulation of IL-6 mRNA. Finally, regarding the interrelation between the production of IL-1 and PGE₂, it was reported that IL-1 and PGE₂ are produced by separate subsets of human monocytes. The interrelationship between the production of cytokines and eicosanoids is given in Fig. 2.

Effect of tumour burden on production of macrophage cytokines and eicosanoids

The functions of tumour associated macrophages (TAM) have been investigated extensively (for reviews see Refs. 65, 66). It was suggested that in situ macrophages may affect the biology of neoplastic tissues in various ways besides tumour killing, by producing growth factors, by interaction with haemostatic mechanisms, by release of mutagenic reactive oxygen intermediates and neutral proteinases, and by their capacity to induce angiogenesis.

The effect of tumour burden on production of macrophage cytokines and eicosanoids was examined in a series of experimental systems and in cases of human cancer.

Experimental studies: It was reported that during tumour growth in rats (subcutaneous implantation), cyclooxygenase or thromboxane synthase is inhibited, whereas C5 and C12-lipoxygenases of the alveolar macrophages are activated. A transient increase of 12-HETE and LTC₄ production in murine peritoneal macrophages was also reported in mice implanted subcutaneously with B16 melanoma cells. Tumour-host derived macrophages were found to suppress a series of events including activation of T cells, natural killing (NK) cells and lymphocyte activated killer (LAK) cells, and generation of tumoricidal activity in normal syngeneic murine splenic macrophages cultures in the presence of LPS. The suppressive effects were correlated with an increase in PGE₂ secretion by tumour-bearing host macrophages.

The role of prostaglandin secretion by macrophages from mice bearing syngeneic tumours was also supported by other authors. Thus, splenic and peritoneal macrophages collected from mice bearing different syngeneic tumours secreted large amounts of PGE₂ as a result of their interaction with the tumours. These macrophages were immunosuppressive and their suppressive activity was significantly reduced by IND thus proving that the suppressive effect was due to increased release of prostaglandin. In another study, it was shown that induction of spleen cell cytotoxic capacity toward murine Lewis carcinoma was due to an increase in PGE₂ levels. The inhibitory effect was prevented by pretreatment of tumour-bearing mice with IND.

The effect of tumour burden on the ability of macrophages to secrete cytokines was also examined. Continuous alveolar macrophage (AM) and tumour infiltrated (TIM) cell lines were generated from C57BL/6J mice and tested for their potential to secrete IL-1, TNF-α or IL-1 following exposure to rMulFN-γ and LPS. Neither cell line secreted substantial amounts of IL-1 or TNF-α but secreted large amounts of IL-6. Peritoneal macrophages from sarcoma-bearing mice produced progressively less IL-1 as tumour burden increased. Administration of LPS to tumour-bearing mice early after tumour transplantation, resulted in reduced tumour growth and prevented the down-regulation of in vitro IL-1 production by peritoneal macrophages. Thus, it seems that a specific defect in IL-1 production was associated with increasing tumour...
In another study it was concluded that murine tumour-infiltrating macrophages isolated from the lungs of mice bearing lung B16F10 metastases responded as normal alveolar macrophages to biological response modifiers in relation to induction of tumoricidal activity and to secretion of IL-1 and TNF-α. However, tumour associated macrophages (TAM) isolated from five cases of murine sarcomas showed a limited capacity to produce and release IL-1 as compared to peritoneal macrophages upon stimulation with LPS. The role of TNF-α release by TAM in specific defence against the inoculated tumour was questioned by various authors. Thus TAM from mice bearing EMT6 tumours exhibited high anti-WEHI-164 activity due to release of TNF-α but was not effective against the EMT6 tumour. Similarly, TAM in a murine fibrosarcoma model produced TNF-α but this production did not affect the tumour growth.

Human studies: Indirect indication of the role of prostaglandin production by macrophages from cancer patients was provided by data showing that monocyte-derived macrophages isolated from blood of cancer patients can be rendered cytotoxic by treatment with IND. Apparently not all macrophages collected from cancer patients could be rendered cytotoxic against allogeneic or autologous tumour target cells, presumably because they were nonresponsive and/or because of the presence of a plasma inhibitory factor. In another work, it was reported that peripheral and bone marrow enriched fraction of monocytes produce high levels of PGE2. However, the increased release of PGE2 was not correlated to clinical or pathological findings.

The production of IL-1 and TNF-α by tumour-associated mononuclear leukocytes (TAML) and peripheral blood mononuclear leukocytes (PBML) in cancer patients was determined. Stimulation by LPS induced production of similar levels of TNF-α in TAML and PBML but production of IL-1 was markedly suppressed in LPS-stimulated tumour-associated mononuclear leukocytes (TAML). In another study the release of IL-1 and IL-6 by TAM from ascites and solid tumours of human ovarian carcinoma was investigated. It was found that TAM release spontaneously or upon LPS stimulation high amounts of IL-6 whereas they were poor producers of IL-1. LPS-induced production of TNF-α by peripheral blood macrophages was impaired in cases of breast cancer. On the other hand, secretion of TNF-α by monocytes from patients with malignant brain tumours was significantly greater by comparison with monocytes from normal individuals. Increase in secretion of TNF-α and of IL-1 was also reported by alveolar macrophages from patients with lung cancer as compared with secretion by peripheral blood monocytes from the same patients or by alveolar macrophages from patients with nonmalignant disorders. However, alveolar macrophages from lung cancer patients were found to be impaired in their ability to develop antitumour cytotoxic activity compared with either the peripheral blood monocytes from the same patients or alveolar macrophages from patients with nonmalignant lung disorders. An increase in the level of TNF-α was also found in tumour-infiltrating macrophages in human colorectal adenocarcinoma. The increase in TNF-α levels correlated with an increase in the size of the primary tumour.

Some work was dedicated to determining the interrelationship between the production of TNF-α and PGE2 by monocytes from cancer patients. LPS-incubated monocytes from cancer patients with malignancies of the digestive tract, produced high levels of TNF-α and PGE2 when cultured in medium with foetal bovine serum. Addition of cancer-patient plasma to the medium suppressed markedly TNF production but induced a prominent enhancement of PGE2 production. Plasma of cancer patients did not exhibit TNF-α activity but such plasma contained increased levels of PGE2. However, although low amounts of exogenous PGE2 suppressed TNF-α production by normal monocytes, addition of 10% plasma-containing PGE2 did not induce suppression of TNF-α production, thus indicating that some unidentified factor(s) in the plasma of cancer patients modulates the TNF-α and PGE2 production in these patients. Correlation between production of TNF-α and PGE2 by peripheral blood monocytes was also studied in patients with bladder cancer. It was found that these patients had either higher TNF-α production or higher PGE2 production. A shift in macrophage population was due to tumour growth in BALB/c mice: immunosuppression in the tumour-bearing host was caused at least in part to the inability of Mac-1+ and/or Mac-3+ to control production of PGE2 by Mac-2+ macrophages. Certain tumour-cell membrane constituents were found to activate human monocytes for TNF-α synthesis.

In view of the wide variation in the results on release of macrophage cytokines and prostaglandin by monocyte-macrophages and tumour-associated macrophages from cancer patients, it still seems difficult to draw final conclusions on the role of this release in clinical settings of neoplasia. It seems that increased release of PGE2 is usually found in TAM and may be correlated to an increase in the severity of the disease. Thus, high prostaglandin production in tissues surrounding human breast tumours is
correlated with high metastatic potential for neoplastic cells. Successful therapy with IND and with a combination of IND and IL-2 was explained by abrogation of prostaglandin-mediated suppression of NK activity and IL-2 production.

Production of eicosanoids and cytokines by tumour cells

In view of the role played by eicosanoids and cytokines in expression of antitumour activity it seems likely that intrinsic production of these compounds by tumour cells may affect the resistance to tumour development in tumour-bearing animals and in human neoplasia.

First reports indicated that BP8/P1 murine ascitic tumour and, to a less extent a subcutaneously implanted S180 rat tumour, produced PGE2. However, the role of PGE2 production in the development of the tumour remains uncertain because induction of a decrease in PGE2 levels by IND did not affect appreciably the tumour growth. In more recent work it was shown that certain murine tumours produce prostaglandins and that their response to IND therapy was directly related to their ability to produce prostaglandin.

Production of PGE2 by EL4 leukaemia cells from C57BL/6 mice was also correlated to the extent of migration and dissemination of the tumour. Prostaglandin biosynthesis was also found to occur in established cell lines derived from human lung, colorectal adenocarcinoma, and ovarian adenocarcinoma. A difference in the amount of PGE2 released was found between cancer cells metastasizing into rat liver or rat kidney. It was assumed that this difference may be related to the mechanism of cancer metastases or to selection of the organ in which metastases occur.

Tumour cells were reported to also produce cytokines. Thus, tumours from cachectic mice produced both TNF-α and IL-1α in vivo as documented by the presence of TNF-α and IL-1α mRNA and immune-reactive protein for IL-1α. The tumour cells also produced TNF-α and IL-1α in long-term cultures but not IL-6. Secretion of TNF-α by human leukaemic cells was also reported. A myeloma cell line established from the pleural effusion of a myeloma patient secreted both TNF-α and IL-6 and these cytokines induced proliferation of the cell line. In IL-6 production a dual effect was described: the murine MH134 tumour cells produced high amounts of IL-6 whereas the murine CSA1M tumour produced only marginal levels of IL-6. However, both tumours induced production of IL-6 by T cells in the tumour-bearing host. Leukaemic cells from patients with acute myeloid leukaemia produced both IL-6 and IL-1. Prostatic carcinoma cell lines expressed the IL-6 receptor and secreted IL-6.

Squamous cell carcinoma cell lines produced both IL-1 and IL-6. An interesting situation was described with the murine P815 mastocytoma: this line produces TNF but, at the same time, this was one of the first tumour cell lines which was found to be sensitive to exogenous TNF. It seems likely that production of prostaglandins and macrophage cytokines as well as induction of their production by macrophages in tumour-bearing hosts plays a role in the development of the tumour in vivo. However, the direct relationship between neoplasia and the ability of tumour cells to produce and/or induce production of macrophage eicosanoids and cytokines is not clear yet.

Interactions between macrophage cytokines and eicosanoids in expression of antitumour activity

Interactions between TNF-α, IL-1 and IL-6: TNF-α alone is cytostatic or cytotoxic for a wide range of murine and human tumour-cell lines. On the other hand, TNF had no effect on a wide variety of murine and human tumour-cell lines and enhanced the growth of various normal cell lines. Moreover, a heterogeneous cytotoxic response of TNF-α was described for various cell lines isolated from the same single neoplasm of human colorectal carcinoma or renal cell carcinoma. Membrane-associated TNF was shown to be the lytic principle of activated macrophages cytotoxic for TNF susceptible tumour cells. The complexity of TNF antitumour activity is also shown by findings that TNF-α mediates the enhanced cytotoxicity induced in monocytes by IFN, IL-1 and by TNF itself. Treatment of human monocytes with TNF increased their cytostatic ability in a dose-dependent manner against P815 murine mastocytomas. IL-1 was also reported to be cytotoxic for several tumour-cell lines. However, IL-1 can act also as an autocrine growth factor for acute myeloid leukaemia cells.

The fact that TNF-α and IL-1 are both produced by activated macrophages, and that TNF-α itself is an inducer of IL-1 production, prompted investigations devised to determine possible synergistic and additive antitumour effects of combinations of the two cytokines. Combination of TNF-α and IL-1 synergistically or in additive manner inhibited the growth of human A-375 melanoma cells. In another study, it was claimed that enhancement of antitumour human monocyte activity by combined TNF-α and IL-1β was less than additive. We found that a combination of TNF-α and IL-1 had an additive effect on antitumour cytostasis against WEHI-3B murine.
tumour cells. It should be noted that TNF-α and IL-1 represent only a fraction of a wider spectrum of macrophage cytokines involved in expression of antitumour activity of macrophages.

Antitumour activity of IL-6 against human breast carcinoma and leukaemia/lymphoma cell lines and in vivo against four murine metastatic tumours has been reported. On the other hand, autocrine generation and requirement as a growth factor for human multiple myelomas and for human renal cell carcinomas has also been described.

IL-6 production is induced by LPS which also stimulates production of TNF-α and IL-1, IL-1 induced synthesis of IL-6 in human blood monocytes and TNF-α induced IL-6 in sera of cancer patients and tumour-bearing mice. Moreover, it was found that IL-6 is involved in IL-1 induced activities as pyrogenicity and stimulation of thymocyte proliferation. However, there are apparently few data on synergistic, additive or antagonistic effects of combination of IL-6 with either TNF-α or IL-1 on tumour cells. It was claimed that systemic administration of low doses of IL-6 in combination with sub-therapeutic doses of TNF to mice bearing a weakly immunogenic syngeneic tumour resulted in marked regression and some cure.

Interactions between cytokines and eicosanoids: Modulation of production of various arachidonic acid derivatives is by itself related to induction of antitumour activity in macrophages. Thus, in vitro treatment of murine peritoneal macrophages with IND, a cyclooxygenase inhibitor, induced antitumour cytostatic activity against a murine plasmacytoma and this effect was increased when LTB₄ was added to the cultures. The IND stimulation of macrophage cytostasis against the murine plasmacytoma was enhanced by endogenous metabolites of lipooxygenase and counteracted by PGE₂. Induction of macrophage cytostasis towards P815 mastocytoma by calcium ionophore was reversed by specific inhibition of lipooxygenase. In other work it was shown that LTC₄ is an essential 5-lipooxygenase intermediate in A23187-induced antitumour cytostatic activity and that addition of L-serine to cultures stimulated by calcium ionophore increased both the accumulation of LTC₄ in murine macrophages as well as their antitumour activity. LPS-induction of macrophage tumour killing was counteracted by PGE₂ but not by PGI₁.

It should be noted that there are contradictory reports concerning the effect of prostaglandin production by macrophages tumour cells, and the direct effect of prostaglandins on tumour growth. Thus, it was reported that PGE could inhibit DNA synthesis and tumour cell replication in vitro and tumour growth in vivo. PGA also inhibited tumour growth in vitro and in vivo. However, in spite of the fact that induction of antitumour activity in macrophages by LPS was associated with an increase in PGE₂ and thromboxane production, these compounds did not seem essential for the expression of antitumour activity, as induction of antitumour activity took place and was even enhanced in the presence of indomethacin. It has been reported also that addition of exogenous PGE₂ to murine peritoneal macrophages did not alter the ability of these cells to produce high levels of tumour-cell lysis when stimulated with LPS. Finally, contrary to suggestions in Refs. 143 and 144 blockade of prostaglandin synthesis by indomethacin prevented the effect of LPS and led to a substantial resumption of target growth in the presence of activated macrophages. A differential effect of PGE₂ on expression of macrophage antitumour activity was described in relation to the state of the macrophages: culture conditions that caused increased PGE₂ production by activated macrophages resulted in inhibition of their tumoricidal activity but production of high levels of PGE₂ by resident and peptone elicited macrophages was associated with an increase in antitumour activity.

The contradictory results described may be due to differences in sources of macrophages, in types of target tumour cells and in the physiological state of the effector cells.

We and others have investigated the interrelation between eicosanoids and TNF-α or IL-1β in expression of antitumour activity. Human peritoneal macrophages collected from CAPD patients during an intercurrent infectious inflammation showed a sharp drop in cAMP and a decrease in production of cyclooxygenase metabolites. On the other hand, they were primed in an inflammatory environment so that they were much more cytostatic against murine tumour cells than macrophages collected during inflammation free periods. When macrophages collected during inflammation were cultured with LPS, their antitumour cytostasis against two murine tumour-cell lines was markedly increased and this increase was associated with increase in TNF-α and IL-1β release.

Interrelation between eicosanoids and TNF-α or IL-1β in expression of antitumour activity was also examined by addition of the cell-free compounds to cultures of tumour cells. Interestingly, concomitant addition of PGE₂ enhanced the antitumour effect of IL-1β on a IL-1β susceptible WEHI-3B murine tumour, whereas addition of LTC₄ inhibited the antitumour effect of IL-1. The synergistic effect between prostaglandins and cytokines in expression...
of antitumour activity was also observed when the WEHI-3B murine tumour cells were first treated with the cytokine and afterwards with the prostaglandin: pretreatment with IL-1β rendered the tumour cells susceptible to PGE₂ or PGI₂ whereas only susceptibility to PGE₂ was increased by pretreatment with TNF-α. Other authors found that Kupffer resident rat cells and Kupffer inflammatory murine liver cells produced both TNF-α and PGE₂. Upon activation with IFN-γ + LPS (for mouse resident Kupffer cells) or with LPS alone (for rat Kupffer cells and mouse inflammatory Kupffer cells) the cells produced more PGE₂ and more TNF-α. However, PGE₂ did not play a role in tumour because treatment with indomethacin increased the TNF induced killing.

**Therapeutic implications**

Work on therapeutic effectiveness was mostly concentrated on ways to affect *in vivo* prostaglandin production and on the possibility of using TNF-α either alone or in combination with other agents for therapy. The therapeutic effectiveness was examined in three systems: against animal tumours, against xenogeneic transplants of human tumours in nude mice and in clinical trials in cancer patients.

**Experimental animal tumours:** Prostaglandins have been implicated as enhancers of tumour growth and spread. The sources of prostaglandin were tumour cells, and/or cells of monocyte-macrophage lineage. Accordingly, it was assumed that inhibition of prostaglandin biosynthesis by cyclooxygenase inhibitors might have a beneficial therapeutic effect.

Most of the work on the basis of this assumption was done by looking on the therapeutic effect of the cyclooxygenase inhibitor IND as downgrading PGE₂ production. Thus, it was shown that IND therapy prevents tumour metastasis of a mouse mammary carcinoma cured B16F10 murine melanoma lung metastasis when given in combination with IL-2, and cures murine Ehrlich ascites tumours when administered in combination with LAK cells and IL-2. The effectiveness of IND therapy was correlated to the ability of murine tumours to produce prostaglandins. However, it was doubted if the therapeutic effectiveness of indomethacin is due to inhibition of PGE₂ production. IND treatment prolonged survival of sarcoma-bearing mice without, however, having an effect on serum concentrations of IL-6 which increased progressively with increase of the tumour.

Tumour necrosis-like activities have been described since the initial observations in the 1890s on regression of tumours in patients with concomitant bacterial infections or injected with bacterial culture filtrates (for review see Ref. 3). After its first characterization as tumour necrosis factor produced by macrophages, its activity against a long series of human and murine tumours was demonstrated *in vitro*. The next obvious step was to determine the therapeutic effectiveness of TNF-α in tumour-bearing hosts. rHuTNF-α was shown to be effective against subcutaneously implanted murine MethA sarcoma but not against the same tumour injected i.p. The curative effect of TNF-α was attributed to its ability to induce local haemorrhages because of its effect on the endothelial cells. It should be noted also that TNF-α therapy involved generation of specific cell-mediated antitumour immunity by a still undefined mechanism.

In another experimental system the antitumour effect of recombinant murine TNF-α given either by continuous i.v. infusion or by repeated i.v. injections was determined in a rat liver metastases model. Only early continuous infusion had an effect on the number of liver metastases presumably because higher doses of TNF-α were tolerated by this schedule. The conclusion of the authors was that TNF-α by itself is not a very efficient antitumour agent and it might be necessary to use TNF-α in combination with other antitumour agents. A similar conclusion of more therapeutic effectiveness of TNF in combination with other treatments was in the case of TNF radiotherapy by comparison with TNF-α alone in rat renal-cell carcinoma, or a combination of TNF-α with the interferon-inducer bropirimine in rat colon cancer. Sequential use of anti-CD3, IL-2 and TNF for LAK induction and maintenance potentiated antitumour activity against a pulmonary metastatic model in mice.

Another interesting additive effect was described after combined treatment with activated macrophages and a low dose of TNF-α in mice bearing Lewis lung carcinoma or EMT6 sarcoma. A synergistic therapeutic effect was also described in tumour-bearing mice treated with low doses of IL-6 in combination with subtherapeutic doses of TNF-α. The therapeutic use of TNF-α in tumour-bearing mice was found to be affected by an increase in the toxicity of TNF-α in tumour-bearing hosts and by induction of tolerance to TNF-α. A side effect of antibodies to TNF-α was reported: passive immunization with anti-TNF antibodies abrogated partially IL-2 toxicity in tumour-bearing mice. Finally, the effect of TNF therapy might differ in context to the strain of mice: the curative effect of TNF was stronger against MethA sarcomas implanted in BALB/c nu/nu mice than into BALB/c nu/nu mice, when TNF was injected i.v. and similar when injected i.t.
therapeutic approach was described recently: a novel chimera tumour necrosis factor (TNF-S-TN) constructed by connecting a modified recombinant human TNF-α (rTNF-S) with thymosin β4 was suggested to be a promising approach for obtaining molecules that more favourably attack tumours than conventional rTNF.164

Xenografts of human tumours in nude mice: TNF was also found to be effective against human malignant melanoma, human gastric cancer and nasopharyngeal carcinoma cell lines implanted in nude mice.165 Combined therapy with IFN-γ and TNF-α was found to be more effective than TNF-α alone against human ovarian cancer cells inoculated in nude mice.165 A similar synergistic effect between IFN (interferon-alpha) and TNF-α was described against a human tumour line causing lung metastasis and intra-abdominal carcinomatosis in nude mice.166 In another study it was found that combined treatment with TNF-α and etoposide was efficient against a human renal cell carcinoma implanted in athymic mice.167

Clinical trials: The findings on cytotoxic effects of cytokines (especially TNF-α) on a wide array of murine and human tumour cell lines in vitro and the results on therapeutic effectiveness against murine tumours and against human tumour cells implanted in nude mice prompted the start of clinical trials in various cancer patients. Unfortunately the results in clinical trials were not very spectacular. In one of the first studies a certain improvement due to TNF-α therapy was observed in three out of 18 patients: two cases of lymphoma and one case of Hodgkin’s.168 Febrile reactions and other side effects occurred in most of the patients and they could be prevented by steroids and IND.168 However, according to the authors, “such prophylaxis may not be desirable because its influence on possible therapeutic benefits is unknown”. Some beneficial response in cases of gastric cancer and non-Hodgkin’s lymphoma were also reported by other authors.169 Side effects to TNF-α were recorded and could be ameliorated by IND or ketoprofen.169 In cases of B-lymphoma some improvement was detected in one out of 26 patients and side effects to TNF-α were again observed.170 In another study no antitumour response was detected in 29 cancer patients.171 In two cases out of 16 evaluable patients with disseminated cancer, TNF-α therapy had some antitumour effect: regression of a neck lesion in one case and resolution of malignant ascites in another.172 The results on various clinical trials with TNF-α until 1988 were summarized at a seminar of the 19th German Cancer Congress: “Although TNF as a single agent is unlikely to be of major benefit for patients with cancer, it has to be concluded that the great expectations which were particularly due to its dramatic effect in the murine sarcoma model leading to the designation ‘TNF’ have been disappointed”.173

More clinical trials have been performed with TNF-α in recent years. In a phase II trial with 22 eligible patients with metastatic colorectal adenocarcinoma, treatment with TNF-α was not effective.174 A more promising result was obtained in a clinical trial with TNF-α including 29 patients with refractory malignant ascites: out of 29 patients, 22 responded with a complete (16) or partial (6) resolution of their ascites.175 Recently, in one out of 53 patients with advanced malignancies a partial response to TNF was observed in one patient with colorectal carcinoma.176 In another recent study no clinical efficacy of TNF-α was found in a phase I trial with patients with advanced cancer.177 Rather disappointing results concerning the use of human recombinant TNF-α for cancer therapy were reported recently by two groups: no objective responses were observed in 22 cases of advanced carcinoma of the pancreas178 and no significant antitumour activity of rHTNF-α was detected in 127 eligible patients with diverse metastatic malignancies.179 Another group concluded that rHTNF-α has only modest antitumour activity in 26 patients with renal cell carcinoma.180

A more promising approach for therapy was suggested by using TNF-α in combination with other interleukins.181,182 This was suggested by results obtained in vitro and in experimental systems in vivo with such combinations. However, in only one patient with melanoma and one patient with mesothelioma (out of 36 patients), was some response observed to combined treatment of recombinant TNF-α with recombinant IFN-γ,183 and two partial responses were seen in a study with combined recombinant IL-2 followed by recombinant TNF therapy in 31 patients with metastatic malignancies.184

The use of TNF-α therapy is handicapped by the toxicity of the agent and by its extremely pleiotropic biological effects. It should be also noted that in most clinical trials with TNF-α most of the patients were found refractory to other kinds of treatments and were in an advanced stage of disease. Moreover, it was reported that sera of cancer patients may contain factor(s) inhibiting TNF.185,186 It has been also reported that treatment with TNF-α might induce decreases of NK cell activity and of monocyte production in cancer patients.187

The general conclusion from clinical trials until now is that therapy with TNF-α is still in its infancy. Apparently, combinations of various interleukins for cancer therapy might be more promising. A new approach was suggested in the recent years consisting of therapy by monocytes from cancer patients induced to mature in vitro to macrophages
possessing antitumour cytotoxic activity.\textsuperscript{188,189} In view of the findings that such macrophages secret various cytokines,\textsuperscript{184} it might be that the activated macrophages continue to secrete \textit{in vivo} interleukins cytotoxic for cancer cells.

**Concluding Remarks**

A vast amount of material has accumulated on the interrelationship in production between macrophages cytokines, macrophage cytokines and eicosanoids, production of these products by tumour cells and the effect of tumour burden on their production. The expression of interrelationship between macrophage cytokines themselves and between macrophage cytokines and eicosanoids was also extremely investigated. In certain instances the results obtained in \textit{in vitro} systems were also expressed \textit{in vivo} in various therapeutic schedules in mice bearing syngeneic tumours on xenografts of human tumour-cell lines. Unfortunately, the promising results obtained \textit{in vitro} and in experimental systems \textit{in vivo} have not yet been well duplicated in clinical trials. Much more work has still to be done in defining optimal conditions for the use of single interleukins and (more likely) combinations of interleukins for effective anticancer therapy. Some of the negative and positive aspects of use of one of the most commonly tested cytokine (TNF-\(\alpha\)) is schematically represented in Fig. 3. It is also possible that other approaches such as therapy with cells able to produce \textit{in vivo} a wide array of cytokines (macrophages) or devising ways for effective induction of cytotoxic interleukins \textit{in vivo} by a cancer patient’s own cells might lead to more promising results.

**Fig. 3.** Negative and positive aspects of the TNF\(\alpha\) anticancer therapy.

**References**

1. Metchnikoff E. In: \textit{Immunity in Infectious Disease}. Cambridge University Press, London, 1905.

2. Adams DC, Hamilton TA. Phagocytic cells: cytotoxic activities of macrophages. In: Gallin JL, Goldstein DM, Snyderman R, eds. \textit{Basic Principles and Clinical Correlates}. New York: Raven Press, 1988: 471-492.

3. Roff MR, Gifford GE. Tumour necrosis factor. In: Pick E, Landy M, eds. \textit{Lymphokines}. Academic Press, 1991: 21: 235-272.

4. Carswell EA, Old LJ, Kassel RJ, Green S, Williams AO. An endotoxin-induced serum factor that causes necrosis of tumors. \textit{Proc Nat Acad Sci U S A} 1975; 72: 3666-3670.

5. Gery I, Gershon RH, Waksman BH. Potentiation of the T-lymphocyte response to mitogens. \textit{I. The responding cell}. \textit{J Exp Med} 1972; 136: 128-142.

6. Gery I, Waksman BH. Potentiation of the T-lymphocyte response to mitogens. \textit{II. The cellular source of potentiating mediator(s)}. \textit{J Exp Med} 1972; 136: 143-155.

7. Aarden LA, Breuner TK, Cerottini JC, \textit{et al.} Revied nomenclature for antigen-nonspecific T-cell proliferation and helper factors. \textit{J Immunol} 1979; 123: 2928-2929.

8. Weisbeech J, Chernajovsky V, Zeevi M, \textit{et al.} Two interferon mRNAs in human fibroblasts: \textit{in vitro} translation and \textit{E. coli} cloning studies. \textit{Proc Nat Acad Sci U S A} 1981; 77: 7155-7156.

9. Proppert P, Vandenberge P, Caspah S, \textit{et al.} B cell growth modulating and differentiating activity of recombinant human 26-kD protein. \textit{Biol Nucleic Acids} 1981; 2: 71-78.

10. Poupart P, Vandenbeele P, Cayphas S, \textit{et al.} B cell growth modulating and differentiating activity of recombinant human 26-kD protein. \textit{J Immunol} 1987; 139: 71-78.

11. Metchnikoff E. In: \textit{Immunity in Infectious Disease}. Cambridge University Press, London, 1905.

12. Adams DC, Hamilton TA. Phagocytic cells: cytotoxic activities of macrophages. In: Gallin JL, Goldstein DM, Snyderman R, eds. \textit{Basic Principles and Clinical Correlates}. New York: Raven Press, 1988: 471-492.

13. Roff MR, Gifford GE. Tumour necrosis factor. In: Pick E, Landy M, eds. \textit{Lymphokines}. Academic Press, 1991: 21: 235-272.

14. Carswell EA, Old LJ, Kassel RJ, Green S, Williams AO. An endotoxin-induced serum factor that causes necrosis of tumors. \textit{Proc Nat Acad Sci U S A} 1975; 72: 3666-3670.

15. Gery I, Gershon RH, Waksman BH. Potentiation of the T-lymphocyte response to mitogens. \textit{II. The cellular source of potentiating mediator(s)}. \textit{J Exp Med} 1972; 136: 128-142.

16. Gery I, Waksman BH. Potentiation of the T-lymphocyte response to mitogens. \textit{II. The cellular source of potentiating mediator(s)}. \textit{J Exp Med} 1972; 136: 143-155.

17. Aarden LA, Breuner TK, Cerottini JC, \textit{et al.} Revied nomenclature for antigen-nonspecific T-cell proliferation and helper factors. \textit{J Immunol} 1979; 123: 2928-2929.

18. Weisbeech J, Chernajovsky V, Zeevi M, \textit{et al.} Two interferon mRNAs in human fibroblasts: \textit{in vitro} translation and \textit{E. coli} cloning studies. \textit{Proc Nat Acad Sci U S A} 1981; 77: 7155-7156.

19. Proppert P, Vandenberge P, Caspah S, \textit{et al.} B cell growth modulating and differentiating activity of recombinant human 26-kD protein. \textit{Biol Nucleic Acids} 1981; 2: 71-78.

20. Poupart P, Vandenbeele P, Cayphas S, \textit{et al.} B cell growth modulating and differentiating activity of recombinant human 26-kD protein. \textit{J Immunol} 1987; 139: 71-78.
29. Kotloff RM, Little J, Elias JA. Human alveolar macrophage and blood monocytes. J Leuk Biol 1989; 48: 353-361.

32. Lepe-Zuniga JL, Gery I. Production of intra- and extracellular interleukin-1 in cultured human mononuclear phagocytes. Biochim Biophys Acta 1986; 865: 289-295.

28. Bauer J, Ganter U, Geiger T, et al. Regulation of interleukin 6 expression in human monocytes. Proc Natl Acad Sci USA 1988; 85: 8512-8516.

35. Fieren MWJA, Bemdden GJCM, Bonta IL. Endotoxin-stimulated cytokine production in cultured human monocytes and monocyte-derived macrophages. J Leuk Biol 1990; 48: 481-488.

26. Aderka D, Le JM, VilcekJ. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes. J Immunol 1989; 142: 2017-2020.

25. Bauer J, Bauer TM, Kalb T, et al. Regulation of interleukin 6 receptor expression in human monocytes. J Exp Med 1989; 180: 359-365.

22. Bachwich PR, Chensue SW, Larrick JW, Kunkel SL. Tumor necrosis factor, macrophage colony-stimulating factor, and interleukin-1 by human peritoneal macrophages. Eur J Immunol 1989; 19: 1343-1350.

21. Nawrot PP, Bank I, Handley D, Cassimeris J, Chess L, Stern D. Tumor necrosis factor/cachectin/interleukin-1 activity of human alveolar macrophages. J Leuk Biol 1991; 48: 35-42.

49. Sullivan DA, Wang M, Plevy SE, et al. Human mononuclear phagocytes express and secrete IL-6 in response to IL-1 and TNF-alpha. J Immunol 1990; 144: 3880-3885.

45. Schade UF, Engel R, Jakobs D. The role of lipoxigenases in endotoxin-induced cytokine production. Prog Clin Biol Res 1991; 367: 73-82.

50. Schade UF, Engel R, Jakobs D. The role of lipoxigenases in endotoxin-induced cytokine production. Prog Clin Biol Res 1991; 367: 73-82.

57. Otterness IG, Bliven ML, Eskra JD, Reinke M, Hanson DC. The pharmacologic regulation of interleukin-1 production: the role of prostaglandins. Cell Immunol 1990; 119: 297-309.

56. Dinarello CA. The biology of interleukin-1 and comparison to tumor necrosis factor. J Immunol 1988; 141: 2388-2393.

38. Spatafora M, Chiappara G, D’Amico D, et al. Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression: a differential secretion of prostanoiads and interleukin-1 in experimental tumor-bearing mice. J Leukoc Biol 1989; 46: 416-421.

39. Renz H, Gey J, Schmidt A, Gemsa D. Release of tumor necrosis factor/cachectin/interleukin-1 by human monocytes. Immunol Lett 1991; 31: 85-90.

44. Schade UF, Engel R, Jakobs D. The role of lipoxigenases in endotoxin-induced cytokine production. Prog Clin Biol Res 1991; 367: 73-82.

46. Schade UF, Engel R, Jakobs D. The role of lipoxigenases in endotoxin-induced cytokine production. Prog Clin Biol Res 1991; 367: 73-82.

53. Dinarello CA, Bishai I, Rothensteiner J, Coccini F. The influence of lipoxigenase inhibitors on the in vitro production of human leucocytic pyrogen and lymphocyte activating factor (interleukin-1). J Immunol 1988; 141: 63-60.

58. Modern M, Lemaire I. Leukotrienes augment interleukin-6 production in human monocytes. Agents Actions 1991; 34: 8-15.

51. Rola-Pleszczynski M, Lemaire I. Leukotrienes augment interleukin-6 production in human monocytes. Agents Actions 1991; 34: 8-15.

60. Galgani J, Trinchieri G, Crotty T. Prostaglandin E2 suppresses tumor necrosis factor-alpha gene expression: a differential secretion of prostanoiads and interleukin-1 in experimental tumor-bearing mice. J Leukoc Biol 1989; 46: 416-421.

63. Kunkel SL, Bank I, Handley D, Cassimeris J, Chess L, Stern D. Tumor necrosis factor/cachectin/interleukin-1 activity of human alveolar macrophages. J Leuk Biol 1989; 48: 481-488.

62. Dinarello CA, Bishai I, Rothensteiner J, Coccini F. The influence of lipoxigenase inhibitors on the in vitro production of human leucocytic pyrogen and lymphocyte activating factor (interleukin-1). J Immunol 1988; 141: 63-60.

59. Dinarello CA, Bishai I, Rothensteiner J, Coccini F. The influence of lipoxigenase inhibitors on the in vitro production of human leucocytic pyrogen and lymphocyte activating factor (interleukin-1). J Immunol 1988; 141: 63-60.

58. Modern M, Lemaire I. Leukotrienes augment interleukin-6 production in human monocytes. Agents Actions 1991; 34: 8-15.

60. Galgani J, Trinchieri G, Crotty T. Prostaglandin E2 suppresses tumor necrosis factor-alpha gene expression: a differential secretion of prostanoiads and interleukin-1 in experimental tumor-bearing mice. J Leukoc Biol 1989; 46: 416-421.

61. Kunkel SL, Bank I, Handley D, Cassimeris J, Chess L, Stern D. Tumor necrosis factor/cachectin/interleukin-1 activity of human alveolar macrophages. J Leuk Biol 1989; 48: 481-488.
macrophase and tumor infiltrating macrophase cell lines. Int J Cancer 1991; 58: 1099-1111.

74. Moldawer LL, Lunnoroth C, Miel SB, Lundholm KG. Down-regulation of interleukin-1 production by macrophages of sarcoma-bearing mice. J Immunol 1987; 138: 4270-4272.

75. Bruni GD, Sola Y, Wright RB, Pallorini AV. Tumoricidal activity and cytokine secretion by tumor-infiltrating macrophages. J Immunol 1991; 148: 504-708.

76. Petri T, Bocci V, Tzarbouheli A, Erroz A, Mantovani A. An antigen expression and IL-1 activity in murine tumor-associated macrophages. Immunology 1986; 59: 272-337.

77. Wilschanski J, Lord EM. Specificity (EMTS) and non-specific (WEIU-164) cytolytic activity by host cells in infiltrating tumor spheroids. Br J Cancer 1987; 58: 141-146.

78. Wilson KM, Siegel G, Lord EM. Tumor necrosis factor-mediated cytotoxicity by tumor-associated macrophages. Cell Immunol 1989; 123: 158-163.

79. Manzel DN, Janicke R, Westenfelder U, Eichtenacher B, Kist A, Falk M. Tumor-induced tumor necrosis factor production in macrophages. Lymphokine Res 1990; 9: 485-489.

80. Cameron DJ, Rittenbury M, Majerski F. Ability of cancer patient's macrophages to kill autologous tumor targets. Effects of prostaglandin inhibitors on cytotoxicity. Cancer 1984; 85: 2505-2507.

81. Cameron DJ, Storlombo B. The ability of macrophages from head and neck cancer patients to kill tumor cells. Cancer 1984; 64: 2403-2408.

82. Selbourn G, Maranini C, Carozza Y. Increased tumor necrosis factor production in malignant lymphomas. Acta Haematol 1985; 74: 132-136.

83. Economon JS, Kolouch SD, Anderson TM, et al. Interleukin-1 and tumor necrosis factor production by tumor associated macrophages of peripheral mononuclear leukocytes in cancer patients. J Immunol 1988; 52: 712-714.

84. Erroz A, Sirioni M, Chiariello P, Chen ZG, Mengozzi M, Mantovani A. IL-1 and IL-6 release by tumor associated macrophages from human ovarian carcinoma. Int J Cancer 1989; 44: 795-801.

85. Zielinski CC, Mueller G, Tyl B, Tzartucheli E, Kulbata E, Spona J. Impaired ex vivo production of tumor necrosis factor in breast cancer. Cancer 1989; 64: 1944-1948.

86. Barra BF, Rogers LB, Thomasen MJ, Barnett GH, Eres ML. Monocyte tumoricidal activity and tumor necrosis factor production in patients with malignant brain tumors. Cancer Immunol Immunother 1991; 33: 314-318.

87. Sinicropi KP, Harris JE, Casey L, Nawas Y, Braun DP. Impaired tumoricidal activity of alveolar macrophages from patients with non-small cell lung cancer. Cancer 1989; 61: 1035-1044.

88. Namata A, Minagawa T, Asano M, Nakane, Kato H, Tanaka T. Functional evaluation of tumor-infiltrating mononuclear cells. Detection of endogenous interferon-α and tumor necrosis factor-α in human colorectal adenocarcinoma. Cancer Immunol Immunother 1991; 26: 1937-1943.

89. Nara K, Odagiri H, Fuji Mi, et al. Increased production of tumor necrosis factor and prostaglandin E2 by monocytes in cancer patients and its unique modulation by their plasma. Cancer Immunol Immunother 1987; 25: 126-132.

90. Ikenoue J, Matsumoto S, Nishio S, Wada S, Maekawa M. Correlation of tumor necrosis factor production and tumor necrosis factor receptor in human gastrointestinal tract and peripheral mononuclear leukocytes in cancer patients. J Immunol 1988; 52: 712-714.

91. Erroz A, Sirioni M, Chiariello P, Chen ZG, Mengozzi M, Mantovani A. IL-1 and IL-6 release by tumor associated macrophages from human ovarian carcinoma. Int J Cancer 1989; 44: 795-801.

92. Zielinski CC, Mueller G, Tyl B, Tzartucheli E, Kulbata E, Spona J. Impaired ex vivo production of tumor necrosis factor in breast cancer. Cancer 1989; 64: 1944-1948.

93. Barra BF, Rogers LB, Thomasen MJ, Barnett GH, Eres ML. Monocyte tumoricidal activity and tumor necrosis factor production in patients with malignant brain tumors. Cancer Immunol Immunother 1991; 33: 314-318.

94. Sinicropi KP, Harris JE, Casey L, Nawas Y, Braun DP. Impaired tumoricidal activity of alveolar macrophages from patients with non-small cell lung cancer. Cancer 1989; 61: 1035-1044.

95. Namata A, Minagawa T, Asano M, Nakane, Kato H, Tanaka T. Functional evaluation of tumor-infiltrating mononuclear cells. Detection of endogenous interferon-α and tumor necrosis factor-α in human colorectal adenocarcinoma. Cancer Immunol Immunother 1991; 26: 1937-1943.

96. Nara K, Odagiri H, Fuji Mi, et al. Increased production of tumor necrosis factor and prostaglandin E2 by monocytes in cancer patients and its unique modulation by their plasma. Cancer Immunol Immunother 1987; 25: 126-132.

97. Ikenoue J, Matsumoto S, Nishio S, Wada S, Maekawa M. Correlation of tumor necrosis factor production and tumor necrosis factor receptor in human gastrointestinal tract and peripheral mononuclear leukocytes in cancer patients. J Immunol 1988; 52: 712-714.

98. Ikenoue J, Matsumoto S, Nishio S, Wada S, Maekawa M. Correlation of tumor necrosis factor production and tumor necrosis factor receptor in human gastrointestinal tract and peripheral mononuclear leukocytes in cancer patients. J Immunol 1988; 52: 712-714.
129. Miki S, Iwano M, Mihy Y, et al. Interleukin-6 (IL-6) functions as an in vivo autocrine growth factor in renal cell carcinoma. *Peters Letters* 1989; 250: 597-610.

130. Jablons DM, McIntosh JK, Mule JJ, Noordan RP, Rudikoff S, Lotze MT. Inhibition of interferon-γ-interleukin-6 (IL-6) by cytokine administration and detection of circulating interleukin-6 in the tumor-bearing state. *Ann NY Acad Sci* 1987; 517: 157-160.

131. Helle M, Brakenhoff JP, De Groot ER, Aarden LA. Interleukin-6 is involved in interleukin-1 induced activities. *Eur J Immunol* 1988; 18: 957-959.

132. Bonta IL, Ben-Efraim S. Leukotrienes and prostaglandins mutually govern the antitumor potential of macrophages. In: Garaci E, Paoletti R, Santoro MG, eds. *Prostaglandins in Cancer Research*. Berlin: Springer Verlag, 1987; 193-201.

133. Ophir R, Ben-Efraim S, Bonta IL. Leukotriene D4 and indomethacin enhance additively the macrophage cytotoxic activity in vitro. *Int J Tissue React* 1987; 9: 189-194.

134. Bonta IL, Elliott GR, Tak C, Ben-Efraim S. Indomethacin stimulation of murine macrophages by MOPC-315 tumor cells is enhanced by endogenous metabolites of lipoxigenase and counteracted by prostaglandin E2. *Agents and Actions* 1989; 26: 167-169.

135. Hiltén JA, Elliott GR, Tak C. Specific lipoxigenase inhibition reverses macrophage cytostasis towards P815 tumor cells in vitro induced by the calcium ionophore A23187. *Prostaglandins Eicos Fatty Acids* 1988; 34: 187-192.

136. Hiltén JA, Ben-Efraim S, Zijlstra FJ, Bonta IL. Leukotriene C4 is an essential 5-lipoxygenase intermediate in A23187-induced macrophage antitumor cytostatic activity against P815 cells. *Prostaglandins Eicos Fatty Acids* 1989; 35: 197-203.

137. Hiltén JA. Modulation of macrophage antitumor cytostasis by endogenous leukotrienes. PhD Thesis Erasmus University Rotterdam, 1990.

138. Taffet SM, Eurell TE, Russell SW. Regulation of macrophage-mediated tumor cell killing by prostaglandins: comparison of the effects of PGE2 and PGL2. *Prostaglandins* 1982; 24: 763-773.

139. Santoro MG, Philpott GW, Jaife BM. Inhibition of tumor growth in vivo and in vitro by prostaglandin E2. *Nature* 1979; 282: 779-780.

140. Santoro MG, Benedetto A, Jaife BM. Prostaglandin A2 induces differentiation in Friend erythroblast cells. *Prostaglandins* 1979; 17: 699-722.

141. Fassil C, Garaci E, Santoro MG, Santoro L. The effect of PGF2α on the immune response in melanomas-bearing mice. *Prostaglandins* 1980; 19: 897-904.

142. Honn KV, Davidowicz K, Bienowski M, Morgan LR, Marnett LJ. Effects of cytokine administration on tumor cell killing by prostaglandins: comparison of the effects of PGE2 and PGL2. *J Lipid Med 1991* 4: 185-198.

143. Raddasi K, Tenu JP, Pradelles P, Lemaire G. Arachidonate metabolism and activated macrophages: synergism and tissue distribution. *Anticancer Res* 1989; 9: 1185-1190.

144. Krenock JA, McIntosh JK, Mole J, Rosenberg SA. Studies of the mechanism of toxicity of the administration of recombinant tumor necrosis factor α in normal and tumor-bearing mice. *Cancer Immunol Immunother* 1989; 26: 123-128.

145. Fraker DL, Sheppard BC, Norton JA. Impact of tolerance on the antitumor efficacy of tumor necrosis factor in mice. *Cancer Res* 1990; 50: 2261-2267.

146. Fraker DL, Langstein HN, Norton JA. Passive immunization against tumor necrosis factor partially abrogates interferon-γ toxicity. *J Exp Med* 1989; 170: 1015-1020.

147. Haranaka K, Satomi N, Sakurai A. Antitumor activity of murine tumor necrosis factor (TNF) against tumor cells in vivo: anti-proliferative tumor necrosis factor and anti-tumor activities of recombinant human tumor necrosis factor. *J Clin Oncol* 1987; 5: 1942-1951.

148. Scheringa M, Keizer A, Jeekel J, Aarden LA. Antitumor effect of recombinant human tumor necrosis factor. In: Garaci E, Paoletti R, Santoro MG, eds. *Monokines, Eicosanoids and Antitumor activity*. Vol 1991 307: 211-221.

149. Donaldson JT, Keane TK, Poulson SH, Walther JP. Enhanced in vivo cytotoxicity of recombinant human tumor necrosis factor with epoeposide in human renal cell carcinoma. *Uncl Res* 1990; 18: 245-250.

150. Selby P, Holbs S, Vines C, et al. Tumor necrosis factor in man: clinical and biological observations. Br J Cancer 1987; 56: 803-808.

151. Taguchi T. Clinical studies of recombinant human tumor necrosis factor. *Immunobiology* 1987; 178: 37 (abstract).

152. Cleophas FB, Lester TJ, Cooper ES, et al. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. *J Clin Oncol* 1987; 5: 1942-1951.

153. Conover PJ, Flager HS, Dupuis S, Husps RP, Takka H, Mittelman A. Phase I clinical trial of recombinant human tumor necrosis factor. *Cancer Chemother Pharm* 1987; 20: 137-144.

154. Blick M, Sherwin SA, Rosenblum M, Guttman J. Phase I study of recombinant tumor necrosis factor in cancer patients. *Cancer Res* 1987; 47: 2986-2989.

155. Herrmann F. Cytokines in cancer therapy. *J Cancer Res Clin Oncol* 1989; 115: 104-108.

156. Whitehead RP, Fleming T, Macdonald JS, et al. A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: a southwest oncology group study. *J Biol Resp Modif* 1990; 211-221.

157. Aulitzky WE, Tilg H, Gastl G, et al. Recombinant tumor necrosis factor: cytokinewithmultiplebiologicalActivities. *Immunobiology* 1987; 175: 37 (abstract).

158. Donaldson JT, Keane TK, Poulson SH, Walther JP. Enhanced in vivo cytotoxicity of recombinant human tumor necrosis factor with epoeposide in human renal cell carcinoma. *Uncl Res* 1990; 18: 245-250.

159. Scheringa M, Keizer A, Jeekel J, Aarden LA. Antitumor effect of recombinant human tumor necrosis factor. In: Garaci E, Paoletti R, Santoro MG, eds. *Monokines, Eicosanoids and Antitumor activity*. Vol 1991 307: 211-221.
S. Ben-Efraim

182. Kolitz JE, Mortelmans R. The immunotherapy of human cancer with interleukin 2: present status and future directions. Cancer Investigation 1991; 9: 529–542.

183. Negrier MS, Pourrea CN, Palmer PA, et al. Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer. J Immunother 1992; 11: 93–102.

184. Smith II JW, Urbas WJ, Clark JW, et al. Phase I evaluation of recombinant tumor necrosis factor given in combination with recombinant interferon-gamma. J Immunother 1991; 10: 355–362.

185. Gistenza T, Hwang C, Kohr W, et al. Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotxin obtained from the serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci USA 1990; 87: 8781–8784.

186. Ikeda M, Sakagami H, Nishida H, Hatta Y, Fukushima Y. Inhibition of tumor necrosis factor-stimulated human peripheral blood polymorphonuclear cell iodination by sera from various cancer patients. Anticancer Res 1991; 11: 1745–1750.

187. Klat A, Ho AD, Rith U, et al. Decrease of natural killer activity and monokine production in peripheral blood of patients treated with recombinant tumor necrosis factor. Basel 1988; 72: 344–348.

188. Bartholeyns J, Lopez M, Andreesen R. Adoptive immunotherapy of solid tumors with activated macrophages: experimental and clinical results. Anticancer Res 1991; 11: 1201–1204.

189. Andreesen R, Scheibenbogen C, Brugger W, et al. Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. Cancer Res 1990; 50: 7450–7456.

ACKNOWLEDGEMENTS. The work of the author was performed at the Department of Pharmacology, Erasmus University Rotterdam. Studies by the author were supported by the Dutch Cancer Foundation (Koningin Wilhelmina Fonds), Erasmus University Foundation Rotterdam (Stichting Universiteitfonds Rotterdam), by a research fund raised by "Supporters of the Joint Israel-Dutch Medical Research" under the auspices of the Israeli Cancer Association Tel-Aviv, Tel-Aviv, Israel and by the Emil Starkenstein Foundation, Rotterdam. The author's stay in Rotterdam was supported by the Dutch Cancer Foundation, the 'Supporters of the Joint Israel-Dutch Medical Research' and by the Erasmus University Foundation. The author is a fellow of the Lautenberg Center for General and Tumor Immunology, Hadassah Medical School, The Hebrew University Jerusalem, Israel. The author is greatly indebted to Prof. I. L. Bonta, Department of Pharmacology, Erasmus University, Rotterdam, for his continuous advice, most helpful criticism and enthusiastic support. I am indebted to Mr C. Tak for making the drawings. The typescript was prepared by Mrs B. H. M. Busschero Lauw.

Received 8 June 1992; accepted 27 June 1992